These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 35544376)

  • 41. Comparison of combined hepatocellular and cholangiocarcinoma with hepatocellular carcinoma and intrahepatic cholangiocarcinoma.
    Lee WS; Lee KW; Heo JS; Kim SJ; Choi SH; Kim YI; Joh JW
    Surg Today; 2006; 36(10):892-7. PubMed ID: 16998683
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Predictability of preoperative 18F-FDG PET for histopathological differentiation and early recurrence of primary malignant intrahepatic tumors.
    Song JY; Lee YN; Kim YS; Kim SG; Jin SJ; Park JM; Choi GS; Chung JC; Lee MH; Cho YH; Choi MH; Kim DC; Choi HJ; Moon JH; Lee SH; Jeong SW; Jang JY; Kim HS; Kim BS
    Nucl Med Commun; 2015 Apr; 36(4):319-27. PubMed ID: 25564069
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Delayed hepatocellular carcinoma model for end-stage liver disease exception score improves disparity in access to liver transplant in the United States.
    Heimbach JK; Hirose R; Stock PG; Schladt DP; Xiong H; Liu J; Olthoff KM; Harper A; Snyder JJ; Israni AK; Kasiske BL; Kim WR
    Hepatology; 2015 May; 61(5):1643-50. PubMed ID: 25644186
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Association of nonalcoholic fatty liver disease and liver cancer.
    Schulz PO; Ferreira FG; Nascimento Mde F; Vieira A; Ribeiro MA; David AI; Szutan LA
    World J Gastroenterol; 2015 Jan; 21(3):913-8. PubMed ID: 25624725
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Major and ancillary features according to LI-RADS in the assessment of combined hepatocellular-cholangiocarcinoma.
    Granata V; Fusco R; Venanzio Setola S; Sandomenico F; Luisa Barretta M; Belli A; Palaia R; Tatangelo F; Grassi R; Izzo F; Petrillo A
    Radiol Oncol; 2020 May; 54(2):149-158. PubMed ID: 32463393
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Individualized curative treatment for malignant diseases through liver transplantation].
    Schwenk L; Rauchfuß F; Ali-Deeb A; Dondorf F; Rohland O; Ardelt M; Settmacher U
    Chirurgie (Heidelb); 2024 Feb; 95(2):122-128. PubMed ID: 37847311
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pharmacokinetic Analysis of Dynamic Contrast-Enhanced Magnetic Resonance Imaging for Distinguishing Hepatocellular Carcinoma From Cholangiocarcinoma in Pre-Liver Transplantation Evaluation.
    Lin CC; Cheng YF; Chiang HJ; Lazo M; Chang CD; Tsang LL; Yu CY; Hsu HW; Chen WT; Wang CC; Liang JL; Eng HL; Chen CL; Ou HY
    Transplant Proc; 2016 May; 48(4):1041-4. PubMed ID: 27320551
    [TBL] [Abstract][Full Text] [Related]  

  • 48. MRI features of combined hepatocellular- cholangiocarcinoma versus mass forming intrahepatic cholangiocarcinoma.
    Sammon J; Fischer S; Menezes R; Hosseini-Nik H; Lewis S; Taouli B; Jhaveri K
    Cancer Imaging; 2018 Feb; 18(1):8. PubMed ID: 29486800
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Hepatoma of the liver--resection or transplantation?
    Neuhaus P; Jonas S; Bechstein WO
    Langenbecks Arch Surg; 2000 Apr; 385(3):171-8. PubMed ID: 10857487
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Role of liver transplantation in the treatment of unresectable liver cancer.
    Pichlmayr R; Weimann A; Oldhafer KJ; Schlitt HJ; Klempnauer J; Bornscheuer A; Chavan A; Schmoll E; Lang H; Tusch G
    World J Surg; 1995; 19(6):807-13. PubMed ID: 8553670
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Lower rates of receiving model for end-stage liver disease exception and longer time to transplant among nonalcoholic steatohepatitis hepatocellular carcinoma.
    Young K; Aguilar M; Gish R; Younossi Z; Saab S; Bhuket T; Liu B; Ahmed A; Wong RJ
    Liver Transpl; 2016 Oct; 22(10):1356-66. PubMed ID: 27348270
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Radiological features and outcomes of combined hepatocellular-cholangiocarcinoma in patients undergoing surgical resection.
    Chi CT; Chau GY; Lee RC; Chen YY; Lei HJ; Hou MC; Chao Y; Huang YH
    J Formos Med Assoc; 2020 Jan; 119(1 Pt 1):125-133. PubMed ID: 30876788
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cholangiocarcinoma, 10-Year Survival After Liver Transplantation: A Case Report.
    Herrero Torres MA; Dominguez Bastante M; Molina Raya A; Palomo Lopez I; Santoyo Villalba J; Villegas Herrera MT; Becerra Massare A; Brea Gomez E; Zambudio Carroll N; Villar Del Moral JM
    Transplant Proc; 2020 Mar; 52(2):592-593. PubMed ID: 32057500
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Value of color Doppler ultrasound in preoperative planning of the resection of liver tumors].
    Bunk A; Stoelben E; Köhler T; Nagel M; Seager HD
    Langenbecks Arch Chir Suppl Kongressbd; 1997; 114():428-30. PubMed ID: 9574172
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Multi-Center Analysis of Liver Transplantation for Combined Hepatocellular Carcinoma-Cholangiocarcinoma Liver Tumors.
    Dageforde LA; Vachharajani N; Tabrizian P; Agopian V; Halazun K; Maynard E; Croome K; Nagorney D; Hong JC; Lee D; Ferrone C; Baker E; Jarnagin W; Hemming A; Schnickel G; Kimura S; Busuttil R; Lindemann J; Florman S; Holzner ML; Srouji R; Najjar M; Yohanathan L; Cheng J; Amin H; Rickert CA; Yang JD; Kim J; Pasko J; Chapman WC; Majella Doyle MB
    J Am Coll Surg; 2021 Apr; 232(4):361-371. PubMed ID: 33316425
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prognostic influence of the liver hanging maneuver for patients with hepatobiliary malignancies who underwent hepatic resections.
    Nanashima A; Abo T; Takagi K; Arai J; To K; Kunizaki M; Hidaka S; Takeshita H; Sawai T; Nagayasu T
    Eur J Surg Oncol; 2014 Nov; 40(11):1540-9. PubMed ID: 25086991
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Intrahepatic cholangiocellular carcinoma with radiological enhancement patterns mimicking hepatocellular carcinoma.
    Viganò L; Lleo A; Muglia R; Gennaro N; Samà L; Colapietro F; Roncalli M; Aghemo A; Chiti A; Di Tommaso L; Solbiati L; Colombo M; Torzilli G
    Updates Surg; 2020 Jun; 72(2):413-421. PubMed ID: 32323164
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Excess mortality on the liver transplant waiting list: unintended policy consequences and Model for End-Stage Liver Disease (MELD) inflation.
    Northup PG; Intagliata NM; Shah NL; Pelletier SJ; Berg CL; Argo CK
    Hepatology; 2015 Jan; 61(1):285-91. PubMed ID: 24995689
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A successful resection and long-term survival of a patient with intrahepatic recurrences of combined hepatocellular-cholangiocarcinoma: report of a case.
    Eguchi H; Nagano H; Sakon M; Miyamoto A; Kondo M; Arai I; Morimoto O; Dono K; Umeshita K; Nakamori S; Wakasa K; Monden M
    Surg Today; 2002; 32(8):742-6. PubMed ID: 12181730
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Differentiation of intrahepatic cholangiocarcinoma from hepatocellular carcinoma in high-risk patients: A predictive model using contrast-enhanced ultrasound.
    Chen LD; Ruan SM; Liang JY; Yang Z; Shen SL; Huang Y; Li W; Wang Z; Xie XY; Lu MD; Kuang M; Wang W
    World J Gastroenterol; 2018 Sep; 24(33):3786-3798. PubMed ID: 30197484
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.